Liquidia (NASDAQ:LQDA) Insider Sells $673,772.06 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 18,314 shares of Liquidia stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $36.79, for a total value of $673,772.06. Following the transaction, the insider owned 187,640 shares in the company, valued at $6,903,275.60. This trade represents a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Scott Moomaw also recently made the following trade(s):

• On Monday, January 12th, Scott Moomaw sold 20,533 shares of Liquidia stock. The stock was sold at an average price of $37.43, for a total transaction of $768,550.19.

Liquidia Trading Down 4.7%

Liquidia stock opened at $35.03 on Friday. Liquidia Corporation has a 12-month low of $11.26 and a 12-month high of $46.67. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -42.20 and a beta of 0.52. The firm has a 50 day moving average of $37.64 and a 200 day moving average of $31.82. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. The business had revenue of $92.02 million for the quarter, compared to the consensus estimate of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The business’s quarterly revenue was up 3072.4% compared to the same quarter last year. As a group, research analysts predict that Liquidia Corporation will post -1.51 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

Hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia in the 4th quarter valued at $25,000. NewEdge Advisors LLC purchased a new stake in Liquidia in the 2nd quarter worth $25,000. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Liquidia during the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia during the third quarter valued at about $34,000. Finally, Covestor Ltd grew its position in shares of Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on LQDA. HC Wainwright upped their target price on shares of Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Jefferies Financial Group raised their price target on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, January 13th. Oppenheimer boosted their price objective on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research report on Thursday, March 12th. Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Finally, Needham & Company LLC increased their target price on Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and an average price target of $43.44.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).